We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI), raising its bet on the US genomic profiling group’s ability to personalise cancer care.